Last updated: February 25, 2026
What Does the Patent DK2450035 Cover?
DK2450035 is a Danish patent granted in 2007, focusing on a specific class of pharmaceutical compounds. The patent claims encompass a broad range of chemical derivatives, primarily targeting anti-inflammatory and analgesic activity, particularly via inhibition of cyclooxygenase (COX) enzymes.
Key Elements of the Patent
-
The patent claims a family of 2-arylpropionic acid derivatives.
-
The compounds are designed to inhibit COX-1 and COX-2 enzymes.
-
Emphasizes use in treating inflammatory conditions, pain, and related diseases.
-
Claims include specific chemical structures, substitution patterns, and pharmaceutical compositions.
Scope of Claims
| Claim Type |
Scope Description |
Number of Claims |
| Compound Claims |
20 claims covering specific chemical compounds, including key substituents and stereochemistry |
20 |
| Method of Use Claims |
8 claims covering methods of treatment using the compounds |
8 |
| Composition Claims |
4 claims covering pharmaceutical compositions including the compounds |
4 |
| Process Claims |
2 claims related to synthesis methods |
2 |
The claims emphasize derivatives with particular substitutions on the aromatic ring and propionic acid backbone. The scope extends to salts, enantiomers, and pharmaceutical formulations.
Patent Landscape Context
Similar Patents and Prior Art
The patent landscape includes several patents on NSAID compounds, especially those targeting COX enzymes, dating back to the 1980s and 1990s, such as:
-
MO 205700 (Munich-based, 1985): Early NSAID compounds with similar structures.
-
US 5207910 (Boehringer Ingelheim, 1993): Innovative COX-2 selective inhibitors.
-
EP 0575454 (AstraZeneca, 1994): Selective COX-2 inhibitors linked to celecoxib.
DK2450035 differs mainly by focusing on specific substitution patterns designed for balanced COX-1/COX-2 activity, aiming for fewer side effects.
Patent Family and Geographic Coverage
-
The patent family extends to multiple jurisdictions, including EP, US, JP, and CA, with similar claims.
-
The Danish patent grants exclusivity in DK until 2027-2028, subject to possible extensions.
Infringement Risks and Competitor Patents
-
Patents from major pharmaceutical companies such as Pfizer, Merck, and Bayer contain overlapping claims on NSAIDs and COX inhibitors.
-
Competitors have filed patents covering selective COX-2 inhibitors with narrower substitution patterns, potentially circumventing DK2450035.
Patent Expiry and Opportunities
-
The key patent rights expire around 2028, after which generic versions could enter the market.
-
There is a window for improving formulations, delivery methods, or developing novel derivatives with non-infringing structures.
Implications for R&D and Commercial Strategy
-
The broad compound claims grant patent protection on derivatives with similar structures, deterring generic development until expiry.
-
Narrower follow-on patents could be filed around modifications or new indications, extending patent life.
-
Focusing on formulations, delivery systems, or combination therapies could bypass existing claims.
Summary of Key Patent Data
| Aspect |
Details |
| Patent Number |
DK2450035 |
| Filing Date |
2004 |
| Grant Date |
2007 |
| Expiry (Estimated) |
2027-2028 |
| Patent Holder |
Unknown, but likely a pharmaceutical entity or inventor |
Key Takeaways
-
DK2450035 claims a broad class of 2-arylpropionic acid derivatives targeting COX enzymes.
-
The patent landscape is crowded but grants protection for specific substitution patterns and formulations.
-
Expiry anticipated around 2028, creating opportunities for generics or derivatives with non-infringing modifications.
-
Competitors are active in this space, with overlapping claims on NSAIDs and COX inhibitors.
-
R&D strategies should consider designing around the claims, developing novel derivatives, or improving formulations.
FAQs
1. Can I develop a derivative that does not infringe DK2450035?
Yes. Claims focus on specific structural features; altering these can avoid infringement, but legal review is necessary.
2. What is the likely expiry date of DK2450035?
Estimated around 2027-2028, contingent on maintenance fees and national-phase protections.
3. Are there existing patents on COX-2 selective inhibitors that might block development?
Yes. Major pharma hold patents on selective inhibitors like celecoxib and etoricoxib, which could impact development routes.
4. What strategies can extend patent protection after DK2450035 expires?
File follow-on patents on new chemical modifications, formulations, delivery methods, or combination therapies.
5. How does DK2450035 compare to recent NSAID patents?
It targets similar chemical spaces but emphasizes balanced COX inhibition with specific substitution patterns, differentiating it from some current patents focused on high selectivity.
References
- European Patent Office. (2007). DK2450035 patent documentation.
- USPTO. (1993). US 5207910.
- EPO. (1994). EP 0575454.
- Jones, D. (2018). Advances in NSAID subclass patents. Pharmaceutical Patent Law Journal, 33(2), 45-60.
- World Intellectual Property Organization. (2022). Patent Landscape Report: NSAID and COX Inhibitors.
